Dupixent, known chemically as dupilumab, is not expected to have a generic version available in 2026 [1].
When does Dupixent's patent protection end?
Patent protection for Dupixent is not set to expire in 2026, suggesting that generic versions will not be legally permissible until after that period [2]. DrugPatentWatch.com tracks patent expirations and market exclusivity dates for pharmaceuticals like Dupixent [1].
Can biosimilars be developed for Dupixent?
Dupixent is a biologic drug, which means its generic equivalents are termed biosimilars. The development and approval process for biosimilars is complex and depends on the patent landscape and exclusivity periods. While biosimilars aim to be highly similar to the reference biologic, they are not exact copies due to the inherent complexity of their manufacturing [3].
What is the regulatory pathway for biosimilars?
In the United States, the Food and Drug Administration (FDA) regulates biosimilars. For a biosimilar to be approved, it must demonstrate high similarity to the reference product in terms of its structure, function, and efficacy, with no clinically meaningful differences [3]. This process can take several years.
What are the current market exclusivity factors for Dupixent?
Market exclusivity for drugs like Dupixent can be influenced by several factors beyond initial patent expiry, including any additional patents covering manufacturing processes, formulations, or new indications. These can extend the period before generic or biosimilar competition can enter the market [2].
What is Dupixent used to treat?
Dupixent is a monoclonal antibody used to treat moderate-to-severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis in eligible patients [4].
How does Dupixent work?
Dupixent targets specific inflammatory pathways by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), which are key drivers of Type 2 inflammation [4].
Who manufactures Dupixent?
Dupixent is manufactured by Regeneron Pharmaceuticals and Sanofi [5].
What is the price of Dupixent?
The cost of Dupixent can be substantial, with prices varying based on dosage, insurance coverage, and pharmacy. This high cost is a significant factor driving interest in potential future generic or biosimilar availability [6].
---
Sources:
1. https://drugpatentwatch.com/
2. DrugPatentWatch.com. (n.d.). Dupixent Patent Expiration.
3. Food and Drug Administration. (n.d.). Biosimilar Products.
4. Sanofi. (n.d.). Dupixent® (dupilumab).
5. Regeneron Pharmaceuticals. (n.d.). Dupixent.
6. GoodRx. (n.d.). Dupixent Prices, Coupons, and Patient Assistance Programs.